Eads & Heald Wealth Management Decreases Stake in Pfizer Inc. (NYSE:PFE)

Eads & Heald Wealth Management reduced its position in Pfizer Inc. (NYSE:PFE) by 37.1% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 8,142 shares of the biopharmaceutical company’s stock after selling 4,803 shares during the period. Eads & Heald Wealth Management’s holdings in Pfizer were worth $234,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Worth Asset Management LLC purchased a new stake in shares of Pfizer in the first quarter worth about $29,000. Briaud Financial Planning Inc purchased a new stake in shares of Pfizer in the third quarter worth about $30,000. GoalVest Advisory LLC lifted its position in shares of Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 811 shares in the last quarter. Mizuho Securities Co. Ltd. purchased a new stake in shares of Pfizer in the third quarter worth about $34,000. Finally, VisionPoint Advisory Group LLC lifted its position in shares of Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 1,047 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on PFE shares. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Monday. TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a research report on Thursday, January 4th. Guggenheim started coverage on Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective on the stock. Finally, Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Twelve research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $36.88.

Pfizer Price Performance

Shares of NYSE:PFE remained flat at $25.91 during trading on Tuesday. The stock had a trading volume of 5,317,546 shares, compared to its average volume of 42,227,086. Pfizer Inc. has a 52-week low of $25.61 and a 52-week high of $41.33. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The stock has a market cap of $146.72 billion, a price-to-earnings ratio of 71.94, a PEG ratio of 1.16 and a beta of 0.61. The stock has a fifty day simple moving average of $27.27 and a 200-day simple moving average of $28.84.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.19) by $0.29. The firm had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business’s revenue for the quarter was down 41.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.14 EPS. On average, equities research analysts forecast that Pfizer Inc. will post 2.22 EPS for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.